Jan. 5 at 1:29 PM
Aktis Oncology Inc., a clinical-stage biotech developing radiopharmaceutical cancer therapies, plans to raise up to
$212 million in its upcoming U.S. IPO. The Boston-based company filed to sell 11.8 million shares at
$16–
$18 each, implying a market value of about
$840 million at the top of the range. Aktis intends to list on Nasdaq.
The company has previously raised about
$346 million from life-science investors. Major pre-IPO shareholders include MPM (26%), Vida Ventures (14%), EcoR1 Capital (11%), and Blue Owl Capital (7%). Founded in 2021, Aktis focuses on alpha-emitting radiopharmaceuticals for solid tumors. For the nine months ended Sept. 30, the company posted a net loss of
$48.6 million on revenue of
$4.6 million, compared with a
$31.9 million loss on
$554,000 in revenue a year earlier. JPMorgan, Bank of America, Leerink Partners, and TD Securities are lead underwriters.
$BAC $JPM $TD